Processing math: 100%
Mini review Special Issues

Serum Autoantibodies as Biomarkers for Parkinsons Disease: Background and Utility

  • There are no definitive diagnostic tests for early detection, diagnosis and staging of Parkinson's disease (PD). Available methods have thus far failed to yield high accuracy, are expensive, and can be highly invasive to the patient. The use of serum biomarkers for the diagnosis of early-stage PD has the potential to provide an accurate, inexpensive, and non-invasive alternative to conventional tests. Recently, investigations into the role of the immune system in the development of PD and other diseases have led to the identification of potential PD-specific autoantibodies. This mini review focuses on the background and utility of these autoantibodies as diagnostic biomarkers of PD. Advantages of serum biomarkers as well as potential benefits of a blood-based diagnostic test to clinical medicine are discussed.

    Citation: Cassandra A DeMarshall, Abhirup Sarkar, Robert G Nagele. Serum Autoantibodies as Biomarkers for Parkinsons Disease: Background and Utility[J]. AIMS Medical Science, 2015, 2(4): 316-327. doi: 10.3934/medsci.2015.4.316

    Related Papers:

    [1] Alessandro P. Delitala . Autoimmunity in latent autoimmune diabetes in adults. AIMS Medical Science, 2019, 6(2): 132-139. doi: 10.3934/medsci.2019.2.132
    [2] Sapana Shinde, Sayantoni Mukhopadhyay, Ghada Mohsen, Sok Kean Khoo . Biofluid-based microRNA Biomarkers for Parkinsons Disease: an Overview and Update. AIMS Medical Science, 2015, 2(1): 15-25. doi: 10.3934/medsci.2015.1.15
    [3] David Petillo, Stephen Orey, Aik Choon Tan, Lars Forsgren, Sok Kean Khoo . Parkinsons Disease-related Circulating microRNA Biomarkers——a Validation Study. AIMS Medical Science, 2015, 2(1): 7-14. doi: 10.3934/medsci.2015.1.7
    [4] Antonio Conti, Massimo Alessio . Proteomics for Cerebrospinal Fluid Biomarker Identification in Parkinsons Disease: Methods and Critical Aspects. AIMS Medical Science, 2015, 2(1): 1-6. doi: 10.3934/medsci.2015.1.1
    [5] Sok Kean Khoo . Biofluid-based Biomarkers for Parkinsons Disease: A New Paradigm. AIMS Medical Science, 2015, 2(4): 371-373. doi: 10.3934/medsci.2015.4.371
    [6] Vanessa J. White, Ramesh C. Nayak . Re-circulating Phagocytes Loaded with CNS Debris: A Potential Marker of Neurodegeneration in Parkinsons Disease?. AIMS Medical Science, 2015, 2(1): 26-34. doi: 10.3934/medsci.2015.1.26
    [7] Herbert F. Jelinek, Jemal H. Abawajy, David J. Cornforth, Adam Kowalczyk, Michael Negnevitsky, Morshed U. Chowdhury, Robert Krones, Andrei V. Kelarev . Multi-layer Attribute Selection and Classification Algorithm for the Diagnosis of Cardiac Autonomic Neuropathy Based on HRV Attributes. AIMS Medical Science, 2015, 2(4): 396-409. doi: 10.3934/medsci.2015.4.396
    [8] Masoud Nazemiyeh, Mehrzad Hajalilou, Mohsen Rajabnia, Akbar Sharifi, Sabah Hasani . Diagnostic value of Endothelin 1 as a marker for diagnosis of pulmonary parenchyma involvement in patients with systemic sclerosis. AIMS Medical Science, 2020, 7(3): 234-242. doi: 10.3934/medsci.2020014
    [9] Muaz O. Fagere . Diagnostic Utility of Pleural Effusion and Serum Cholesterol, Lactic Dehydrogenase and Protein Ratios in the Differentiation between Transudates and Exudates. AIMS Medical Science, 2016, 3(1): 32-40. doi: 10.3934/medsci.2016.1.32
    [10] K.E. Khalid, Hamdi Nouri Nsairat, Jingwu Z. Zhang . The Presence of Interleukin 18 Binding Protein Isoforms in Chinese Patients with Rheumatoid Arthritis. AIMS Medical Science, 2016, 3(1): 103-113. doi: 10.3934/medsci.2016.1.103
  • There are no definitive diagnostic tests for early detection, diagnosis and staging of Parkinson's disease (PD). Available methods have thus far failed to yield high accuracy, are expensive, and can be highly invasive to the patient. The use of serum biomarkers for the diagnosis of early-stage PD has the potential to provide an accurate, inexpensive, and non-invasive alternative to conventional tests. Recently, investigations into the role of the immune system in the development of PD and other diseases have led to the identification of potential PD-specific autoantibodies. This mini review focuses on the background and utility of these autoantibodies as diagnostic biomarkers of PD. Advantages of serum biomarkers as well as potential benefits of a blood-based diagnostic test to clinical medicine are discussed.


    The coronavirus family comprises a diverse range of viruses that can be found in different animal species, including cats, camels, bats, and cattle. In rare cases, animal coronaviruses can infect humans and spread among them, as has been seen with SARS, MERS, and the current COVID-19 pandemic [1,2]. Since it first emerged in Saudi Arabia in 2012, the Middle East respiratory syndrome (MERS-CoV) has claimed the lives of 1791 individuals, according to various sources [3,4]. Meanwhile, the 2003 outbreak of severe acute respiratory syndrome (SARS) resulted in the deaths of 774 individuals [5].

    Camels have been identified as the primary carriers of the MERS-CoV virus according to scientific research. Human-to-human transmission is the leading cause of MERS-CoV cases, responsible for 75 to 88 percent of all cases, while the remaining cases are caused by transmission from camels to humans. It is important to note that the virus can spread through respiratory discharge from infected individuals, such as coughing. In addition, close contact, including caring for or living with an infected person, can also result in the transmission of the virus. Since the discovery of MERS-CoV in April 2012, there have been a total of 536 reported cases, with 145 resulting in death. This gives a case fatality rate of 27 percent. The majority of cases have been recorded in the Middle East, specifically in countries such as Saudi Arabia, Jordan, and Qatar, as noted in [6]. It is crucial to maintain awareness of this disease and take appropriate precautions, particularly in areas where the virus has been reported, in order to prevent its spread.

    The transmission of MERS-CoV between camels and humans is influenced by various environmental factors. The Hajj and Umrah pilgrimages are significant contributors to the spread of the virus, as these events attract more than 10 million individuals from different parts of the world to Saudi Arabia. Mathematical modeling has proven to be a valuable tool for understanding the outbreak, developing effective control strategies, and exploring the immune response to MERS-CoV. Several modeling studies have been conducted to investigate the MERS-CoV outbreak, as highlighted in [7,8,9]. One of the most extensive MERS-CoV epidemics was documented by Assire et al. in [10], who provided evidence suggesting that the virus can be transmitted from person to person. The Kingdom of Saudi Arabia (KSA) has reported the highest number of cases, with most of the cases being recorded there. It is imperative to take appropriate measures to mitigate the spread of the virus, especially in areas that have reported cases, in order to prevent further outbreaks. The consumption of unpasteurized camel milk, which is a common practice in KSA, is a potential cause of camel-to-human transmission of MERS-CoV, as suggested by [11]. Furthermore, Poletto et al. have proposed that the movement and mingling of individuals during the Hajj and Umrah events may play a significant role in the spread of MERS-CoV, as noted in [12]. Other activities, such as camel racing and the opening and closing of camel markets, have also been identified as potential contributors to the transmission of MERS-CoV. Several researchers have constructed mathematical models to study various diseases and real-world problems, including MERS-CoV, as mentioned in [13,14,15,16]. These models have proven to be useful in predicting the spread of the virus, designing effective control strategies, and exploring the immune response to MERS-CoV. It is important to continue this research in order to better understand the disease and limit its impact on public health.

    This study utilizes the next-generation matrix (NGM) approach to model the transmission and spread of MERS-CoV between humans and camels. The researchers calculate the fundamental reproductive number and determine the local stability of the model using the Routh-Hurwitz (RH) criterion. Furthermore, the global stability of the model is assessed through the Castillo-Chavez and Lyapunov type function methods, and the stability conditions are determined in terms of $ \mathcal{R}_0 $. The parameters that impact the transmission of the disease are analyzed through sensitivity analysis of the fundamental reproductive numbers. On the other hand, there have been numerous effective studies have been conducted related to the modelling of infectious diseases [17,18,19], their stability analyses [20,21,22], bifurcation and chaos properties [23,24,25,26,27,28,29,30].

    In addition, the study employs an optimal control analysis to minimize the number of infected individuals and increase the number of cured individuals in the community. By identifying the factors that contribute to the spread of MERS-CoV, this research can inform effective control strategies and minimize the impact of the disease on public health.

    In this section, we introduce a transmission model for MERS-CoV that accounts for transmission between people-camel and human-human. The model is formulated using a set of differential equations that describe the dynamics of six distinct population groups. These groups include the susceptible population (S(t)), the exposed population (E(t)), the symptomatic and infectious population (I(t)), the asymptomatic but infectious population (A(t)), the hospitalized population (H(t)), and the recovered population (R(t)). To simplify the modeling process, we make the following four assumptions.

    a. All the parameters and variables are non-negative.

    b. Four transmission routes are considered for the disease transmission, which is from individuals symptomatic to asymptomatic, from which to hospitalize, and then reservoir, which are camels for MERS-CoV.

    c. The rate of death because of MERS-CoV is considered in the compartment that contains the infection.

    d. We suppose two types of recoveries, the first one is natural and the second one is with treatment.

    Utilizing the above-considered assumptions, we obtain the non-linear system of ODEs as,

    $ ˙S(t)=ϕη1I(t)S(t)η2ϕA(t)S(t)η3qH(t)S(t)η4C(t)S(t)ϖ0S(t),˙E(t)=η1I(t)S(t)+η2ϕA(t)S(t)+η3qH(t)S(t)+η4C(t)S(t)(ξ+ϖ0)E(t),˙I(t)=ξρE(σ1+σ2)II(t)(ϖ0+ϖ1),˙A(t)=(1ρ)ξE(t)(ν+ϖ0)A(t),˙H(t)=σ1I(t)+νA(t)(σ3+ϖ0)H(t),˙R(t)=σ2I(t)+σ3H(t)ϖ0R(t),˙C(t)=ψ1I(t)+ψ2A(t)θC(t),
    $
    (2.1)

    with the initial conditions

    $ Ics={S(0),I(0),E(0),H(0),A(0),C(0),R(0)}0.
    $
    (2.2)
    Table 1.  The description of control parameters in the considered model (2.1).
    Parameter Description
    $ \phi $ New born ratio
    $ \eta_{1}, \eta_{2}, \eta_{3}, \eta_{4} $ Transmission rates
    $ \xi $ Progression towards Infected $ \mathrm{I}(\mathrm{t}) $
    $ {\rm{ \mathsf{ σ}}}_1 $ Hospitalization rate (symtomatic)
    $ {\rm{ \mathsf{ σ}}}_2 $ Recovery rate (without hospitalization)
    $ {\rm{ \mathsf{ σ}}}_3 $ Recovery rate (hospitalized)
    $ \theta $ Lifetime (Camels)
    $ \psi_1 $ Virus transmission rate from $ \mathrm{C}(\mathrm{t}) $ (by symptomatic)
    $ \psi_2 $ Virus transmission rate from $ \mathrm{C}(\mathrm{t}) $ (by asymptomatic)
    $ \nu $ The rate at which asymptomatic individuals become hospitalized
    $ \varpi_0 $ The natural death rate
    $ \varpi_1 $ The death rate due to MERS-CoV
    $ \rho $ The rate at which exposed individuals become infected

     | Show Table
    DownLoad: CSV

    Consider, $ \mathrm{N}_p(\mathrm{t}) $ which represents the total population of humans in such a manner that $ \mathrm{N}_p(\mathrm{t}) = \mathrm{E}(\mathrm{t})+\mathrm{A}(\mathrm{t})+\mathrm{S}(\mathrm{t})+\mathrm{I}(\mathrm{t})+\mathrm{R}(\mathrm{t})+\mathrm{H}(\mathrm{t}) $, then $ \mathrm{N}_p(\mathrm{t}) $ is bounded with lower bound to be 0 and the upper-bound $ \frac{\phi}{\varpi_0} $, i.e., $ 0\leq \mathrm{N}_p(\mathrm{t})\leq \frac{\phi}{\varpi_0} $.

    Using this fact, we present the following theorem:

    Theorem 1. If $ \mathrm{N}_p(\mathrm{t}) $ represents the number of human and $ 0\leq \mathrm{N}_p(\mathrm{t})\leq \frac{\phi}{\varpi_0} $ and $ \mathrm{N}_p(\mathrm{t})\leq\frac{\phi}{\varpi_0}, $ then suggested model (2.1) is well defined in the region as follows:

    $ ψh={(S,I,E,H,A,R,CR7+,whereNp(t)ϕϖ0,C(ψ1+ψ2)ϕϖ0}.
    $

    Let us adopt $ \mathbb{B} $ as Banach space, and positive $ \mathrm{u} = t_+ $, so

    $ B=ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u),
    $
    (3.1)

    where the norm on the space $ \mathbb{B} $ is supposed to be as $ \|\Pi\| = \sum_{i = 1}^{7}\|\Pi_j\| = (\Pi_1, \Pi_2, \Pi_3, \Pi_4, \Pi_5, \Pi_6, \Pi_7)\in \mathbb{B}. $

    Further, $ \mathbb{B}_+ $ represents cone($ +ive $) of $ \varpi^1(0, \mathrm{u}), $ so from Eq (3.1), $ \mathbb{B}_+ $ is given as

    $ B=ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u)×ϖ1(0,u).
    $

    Hence the state space of system (2.1) yields:

    $ Δ={S,I,E,H,A,C,RB+0Np(t)ϕϖ0,0<S(t)+H(t)+A(t)+R(t)+I(t)ϕϖ0,C(ψ1+ψ2)ϕϖ0}.
    $

    We suppose an operator which is linear as $ {\bf L} $ and vector $ {\rm{ \mathsf{ ψ}}} = (\mathrm{S}, \mathrm{I}, \mathrm{A}, \mathrm{E}, \mathrm{H}, \mathrm{C}, \mathrm{R}), $ implies that $ {\bf L}{\rm{ \mathsf{ ψ}}} = ({\bf L}_i)^T $, here $ i = 1, 2, \ldots, 7 $ where

    $ L1=(dSdtϖ0S,0,0,0,0,0,0),L2=(0,dEdt(ξ+ϖ0),0,0,0,0,0),L3=(0,ξρ,dIdt(σ1+σ2+ϖ0+ϖ1),0,0,0,0),L4=(0,ξ(1ρ),dAdt(ν+ϖ0)A,0,0,0,0),L5=(0,0,σ1,ν,dHdt(σ3+ϖ0)H,0,0),L6=(0,0,σ2,0,σ3,dRdtϖ0R,0),L7=(0,0,ψ1,ψ2,0,0,dCdtθ),
    $

    and domain $ \mathcal{D}({\bf L}) $ is

    $ \mathcal{D}({\bf L}) = \bigg\{{\rm{ \mathsf{ ϕ}}}\in \mathbb{B}: {\rm{ \mathsf{ ψ}}} \in {\bf L}\mathcal{C}[0, \mathrm{u}) $, $ {\rm{ \mathsf{ ϕ}}}(0) = Ics\bigg\} $. Here, $ {\bf L}\mathcal{C}[0, \mathrm{u}) $ represent the set containing continuous functions which is defined on the $ [0, \mathrm{u}) $. Consider $ \mathscr{O} $ is the nonlinear operator, that is $ \mathscr{O}:B\rightarrow B $ defined as,

    $ O(ψ)=(ϕη1ISη2ϕASη3qHSη4CSη1IS+η2ϕAS+η3qHS+η4CS00000).
    $
    (3.2)

    Suppose $ V(\mathrm{t}) = (\mathrm{S}(\mathrm{t}), \mathrm{I}(\mathrm{t}), \mathrm{H}(\mathrm{t}), \mathrm{E}(\mathrm{t}), \mathrm{A}(\mathrm{t}), \mathrm{R}(\mathrm{t}), \mathrm{C}(\mathrm{t})) $ then the suggested system can be written as

    $ dvdt=L(V(t))+O(V(t)),V(0)B,
    $

    where $ V_{0} = (Ics)^T $. Utilizing the results in [31,32], we present the existence of the system's (3.2) solution, so we define following theorem:

    Theorem 2. For each $ V_{0}\in B_+, $ there arises an interval (maximal) $ [0, t_0) $, and unique continuous solution $ V(t, V_0) $, in such a way that,

    $ V(t)=V(0)eLt+eL(tr)O(V(σ)).
    $

    Theorem 3. The suggested system (2.1) is invariant (positively) subjected to the non-negative $ R^7+ $.

    Proof. Consider $ {\rm{ \mathsf{ ψ}}} $ and $ h_1 = (\xi+\varpi_0) $, $ h_2 = ({\rm{ \mathsf{ σ}}}_1+{\rm{ \mathsf{ σ}}}_2+\varpi_0+\varpi_1) $, $ h_3 = (\nu+\varpi_0) $, $ h_4 = ({\rm{ \mathsf{ σ}}}_1+\nu) $, $ h_5 = (\theta\varpi_0), $

    $dϕdt=Lϕ+D.L=[ϖ0000000h100000ξρh20000ξ(1ρ)0h30000σ2νh4000ψ1ψ20h5], D=[ϕ00000].
    $
    (3.3)

    It could be noted from Eq (3.3), matrix $ {\bf D} $ is positive, while the off-diagonal of $ {\bf L} $ are non-negative, so the properties of Metzler type matrix holds. Thus the suggested system is invariant in $ R^7. $

    Theorem 4. We assume a positive initial population value for the problem specified in Eq (2.2) and, if the solutions to the model in Eq (2.1) exist, they will be positive for all $ \mathrm{u} $.

    Proof. Let us consider the first equation

    $ dSdt=ϕη1I(t)S(t)η2ϕA(t)S(t)η3qH(t)S(t)η4C(t)S(t)ϖ0S(t).
    $
    (3.4)

    By constant formula of alternation, we obtain the solution (3.4),

    $ S(t)=S(0)exp[dt(η1I(t)S(t)η2ϕA(t)S(t)η3qH(t)S(t)η4C(t)S(t))]dx+ϕexp[dt(η1I(t)S(t)η2ϕA(t)S(t)η3qH(t)S(t)η4C(t)S(t))]dx×[dt+(η1I(t)S(t)+η2ϕA(t)S(t)+η3qH(t)S(t)+η4C(t)S(t))]dx.
    $

    $ \mathrm{S}(\mathrm{t}) > 0 $, in the same pattern one can present that, the remaining equations in (2.1) are positive.

    The main focus of our study is to examine the mathematical and biological plausibility of the system described in Eq (2.1). To achieve this, we carry out a qualitative analysis of the system dynamics. Initially, we compute the threshold parameter $ \mathcal{R}_0 $, which is commonly referred to as the basic reproduction number. This metric allows us to evaluate the inherent capacity of the disease to spread, and determine whether or not an epidemic will persist or eventually fade out. Additionally, we investigate the equilibria of the system and discuss the factors that lead to system stability.

    In this study, we have performed a qualitative analysis of the suggested system in order to identify the conditions under which it remains stable. To achieve this, we have calculated the equilibria of the mathematical model described in Eq (2.1).

    One of the most important equilibrium points for this system is the disease-free equilibrium (DFE), which represents the state of the system when no disease is present. In order to determine the DFE point for the system, we equate the right-hand side of the equations to zero, with the exception of the susceptible class $ \mathrm{S} $, which we set to its initial value $ \mathrm{S}_0 $. By doing so, we are able to obtain the DFE point, which we denote as $ \mathcal{D}_0 $. This point represents an important baseline for the system, against which we can compare the behavior of the system in the presence of disease.

    Overall, our qualitative analysis of the suggested system has allowed us to gain a deeper understanding of its behavior under various conditions, including the DFE point which is a key reference point for the system.

    $ \mathcal{D}_0 = \bigg(\frac{\phi}{\varpi_0}, 0\bigg). $

    We utilize linear stability to study the dynamics of the DFE point and calculate the condition if the equilibrium point turns towards stability and the model becomes under control.

    The endemic equilibrium (EE) point is expressed by $ \mathcal{D}_1 = (\mathrm{S}^{*}, \mathrm{E}^{*}, \mathrm{I}^{*}, \mathrm{A}^{*}, \mathrm{H}^{*}, \mathrm{R}^{*}, \mathrm{C}^{*}), $ and it occurs in the presence of disease

    $ S=ϕ(ν+ϖ0)ξρ+(σ3+ϖ0)Q((η1+ν(1ρ)(σ1+σ2+ϖ0))ϖ2),E=(σ1+σ2+ϖ0)(Q1)(ξρ)(σ3+ϖ0)QI,I=ξ(1ρ)(σ1+σ2+ϖ0)(R01)(ν+ϖ0)νρ,A=η2ϕξ(1ρ)(σ1+σ2+ϖ0)(ν+ϖ0)ξρQ2I,H=σ1(ν+ϖ0)(1ρ)(R01)(σ3+ϖ0)(ξ+ϖ0)νI,R=σ2(σ3+ϖ0)(ν+ϖ0)ξ+σ1QI(σ3+ϖ0)(ν+ϖ0),C=ψ1(ν+ϖ0)ξρI+ψ2ξ(1ρ)(R01)(ν+ϖ0)ξρ.
    $

    The above equations present that, EE of the model (2.1) exists only, if $ \mathcal{R}_0 $ is greater than one. Thus we state the following theorem.

    Theorem 5. The EE point $ \mathcal{D}_1 = (\mathrm{S}^{*}, \mathrm{E}^{*}, \mathrm{I}^{*}, \mathrm{A}^{*}, \mathrm{H}^{*}, \mathrm{R}^{*}, \mathrm{C}^{*}) $ exists only in case $ \mathcal{R}_0 $ is greater than one.

    The definition of $ (\mathcal{R}_0) $ can be described as the number of individuals who become infected after being in contact with an infected individual in a population that is initially fully susceptible and without any prior infections. If $ \mathcal{R}_0 > 1 $, it means that an epidemic is likely to occur, while if $ \mathcal{R}_0 < 1 $, an outbreak is unlikely. The value of $ \mathcal{R}_0 $ is crucial in determining the strength of control measures that need to be implemented to contain the epidemic. In order to calculate $ \mathcal{R}_0 $ for the suggested model (2.1), we use the method described in [33], we have

    $ \mathcal{F} = \left[ 0η1S0η2ϕS0η3qS0η4S000000000000000000000
    \right], $
    $ \mathcal{V} = \left[ b10000ξρb2000b30b4000σ1νb500ψ1ψ20ϖ2
    \right], $

    where $ b_1 = (\xi+\varpi_0) $, $ b_2 = ({\rm{ \mathsf{ σ}}}_1+{\rm{ \mathsf{ σ}}}_2+\varpi_0+\varpi_1) $, $ b_3 = -\xi(1-{\rm{ \mathsf{ ρ}}}) $, $ b_4 = (\nu+\varpi_0) $ $ b_5 = ({\rm{ \mathsf{ σ}}}_3+\varpi_0). $ $ \mathcal{R}_0 $ represents spectral-radius of NGM $ \bar{H} = \mathcal{F}\mathcal{V}^{-1} $.

    So $ \mathcal{R}_0 $ for model (2.1) is

    $ R0=η1ξρS0Q+η2ϕS0(1ρ)(ν+ϖ0)(ξ+ϖ0)+η3qS0Q1(ν+ϖ0)(σ3+ϖ0)Q+η4S0Q2ϖ2(ν+ϖ0)Q,
    $
    (4.1)

    where

    $ Q=(ξ+ϖ0)(σ1+σ2+ϖ0+ϖ1),Q1=ξϖ20ψ2ξσ21ϖ2ξσ1σ2ϖ2ξσ1ϖ0ϖ2ξσ1ϖ1ϖ2+ξσ1σ3ψ2+ξσ2σ3ψ2+ξσ1ϖ0ψ2+ξσ2ϖ0ψ2+ξσ3ϖ0ψ2+ξσ3ϖ1ψ2+ξϖ0ϖ1ψ2+ρξσ21ϖ2+ξρϖ20ψ2+νρξσ3ψ1+νρξϖ0+ξρσ1σ2ϖ2+ξρσ1ϖ1ϖ2ξρσ1σ3ψ2ξρσ2σ3ψ2ξρσ1ϖ0ψ2+ξρσ3ϖ0ψ1ξρσ3ϖ0ψ2ξρσ3ϖ1ψ2ξρϖ0ϖ1ψ2,Q2=η4S0(ξψ2σ2+ξψ2σ1+ξψ2ϖ0+νξρψ1ξρψ2σ2ξρψ2σ1+ξρψ1ϖ0ξρψ2ϖ0).
    $

    The $ \mathcal{R}_0 $ of this model is composed of four components: transmission from individuals who are symptomatic to those who are asymptomatic, transmission from asymptomatic individuals to those who require hospitalization, transmission from hospitalization to the reservoir (camels for MERS-CoV), and transmission from the reservoir to susceptible individuals. These four modes of transmission collectively determine the risk of disease spread during this epidemic.

    We study the dynamics of the proposed system (2.1) at DFE with aid of Theorem 6 as follows:

    Theorem 6. The DFE point $ \mathcal{D}_0 = (\mathrm{S}_0, \mathrm{I}_{0}, \mathrm{E}_{0}, \mathrm{H}_{0}, \mathrm{A}_{0}, \mathrm{C}_{0}, \mathrm{R}_{0}), $ is asymptotically stable (locally) if $ \mathcal{R}_0\leq1 $.

    Proof. The Jacobian-matrix of the model at DFE point $ (D_0, 0, 0, 0, 0, 0), $ is:

    $ J0=(ϖ00η1Sη2ϕSη3qSη4S0(ξ+ϖ0)η1Sη2ϕSη3qSη4S0ξρ(σ1+σ2+ϖ0+ϖ1)0000ξ(1ρ)0(ν+ϖ0)0000σ1ν(σ3+ϖ0)000ψ1ψ20ϖ2).
    $
    (4.2)

    Characteristic equation of Jacobian matrix (4.2) is:

    $ (ζ+ϖ0)(δ+ζ)(a1ζ3+ζ4+a2ζ2+a4+a3ζ)=0,
    $
    (4.3)

    where

    $ a1=σ1+σ2+νϖ0+σ3ϖ0ν,a2=σ2+ϖ0+ξϖ0σ1(1R0),a3=2ϖ20+σ1+σ2+σ3+ϖ0+νσ1+σ3+σ1ϖ0+σ1ξ+ξ(1ρ)+ξν,a4=η3qSξ(1ρ)+ξνσ1+ϖ0ξ(1ρ)σ1η3Sqϖ0νρ.
    $

    $ a_1a_3a_2 > a_2^2a_4+a_2^2 $ if $ \mathcal{R}_0 < 1 $. By RH criteria the real parts of all the roots for characteristic polynomial $ P({\rm{ \mathsf{ ζ}}}) $ are negative, which shows that $ D_0 $ is asymptotically local stable [34,35].

    The upcoming proof presents the global stability at DFE point $ D_0. $ To analyze the global stability analysis at $ F_0 $ we introduce the Lyapunov function as follows.

    Theorem 7. When the reproductive number $ \mathcal{R}_0 $ is less than 1, the disease-free equilibrium of the system is globally and asymptotically stable.

    Proof. Consider the Lyapunov function as

    $ U(t)=12[(SS0)+E(t)+I(t)+A(t)+H(t)+(CC0)]2+[d1S(t)+d2E(t)+d3A(t)+d4H(t)+d5C(t)].
    $
    (4.4)

    Here $ d_i $ for $ i = 1, 2, 3, 4, 5 $ are arbitrary constants, to be considered after differentiating Eq $ (4.4) $, and using (2.1), so we obtain

    $ U(t)=[(SS0)+E+A+I+H+(CC0)][ϕϖ0Np(t)+ψ1I+ψ2Aϖ2C+QQ1(ϕ(1R0)ϖ0E(t))].
    $

    By considering the $ +ive $ parameter $ d_1 = d_2 = d_3 = QQ_1 $, $ d_4 = \frac{1}{Q_2} $, $ d_5 = \varpi_0 $ and after the interpretation we obtain

    $ U(t)=[(SS0)+E+I+A+H+(CC0)][ϖ0(ϕNp(t))ψ1Iψ2Aϖ2WQQ1(ϕ(1R0)ϖ0E(t))],
    $

    where

    $ F^0 = \frac{bN}{\varpi_0}. $

    $ \mathfrak{U}'(\mathrm{t}) $ is negative when $ \mathrm{S} > \mathrm{S}^0 $ and $ \mathcal{R}_0 < 1 $ and $ \mathfrak{U}'(\mathrm{t}) = 0 $ in case if $ \mathrm{S} = \mathrm{S}^0 $ by the LaSalle's invariance principle [36,37], and $ \mathrm{E} = \mathrm{A} = \mathrm{I} = \mathrm{H} = \mathrm{C} = 0. $ Thus the DFE is globally asymptotic stable in $ F_0. $

    Theorem 8. If the threshold value is greater than 1, then the model (2.1) around EE point $ \mathcal{D}_1 $ is locally as well as globally asymptotically stable.

    Proof. The linearization of model (2.1) around EE point $ \mathcal{D}_1 $ is,

    $ J0=(A0η1Sη2ϕSη3qSη4SA1(ξ+ϖ0)η1Sη2ϕSη3qSη4S0ξρA10000ξ(1ρ)0(ν+ϖ0)0000σ1νA2000ψ1ψ20ϖ2),
    $

    where

    $ A=η1I+η2ϕA+η3qH+η4S,A1=(σ1+σ2+ϖ0),A2=(σ3+ϖ0).
    $

    Using row transformation, we obtain:

    $ J0=(A0η1Sη2ϕSη3qSη4S0Bη1Sη2ϕSη3qSη4S00B1η2ϕSη3qSη4S000B2η3qSη4S0000B3000000B4),
    $
    (4.5)

    where $ \mathfrak{B} = (\xi+\varpi_0)(\eta_1\mathrm{I}^*+\eta_2{\rm{ \mathsf{ ϕ}}} \mathrm{A}^*+\eta_3q\mathrm{H}^*+\eta_4\mathrm{S}^*), $ $\mathfrak{B}_1 = ({\rm{ \mathsf{ σ}}}_1+{\rm{ \mathsf{ σ}}}_2+\varpi_0+\varpi_1)(\xi+\varpi_0)\mathrm{A}^*, \mathfrak{B}_2(\nu+\varpi_0)(\xi+\varpi_0)(\mathcal{R}_0-1)\mathrm{A}^*, $ $ \mathfrak{B}_3({\rm{ \mathsf{ σ}}}_1+{\rm{ \mathsf{ σ}}}_2+\varpi_0+\varpi_1)({\rm{ \mathsf{ σ}}}_3+\varpi_0), $ $ B_4 = \varpi_2\xi{\rm{ \mathsf{ ρ}}}({\rm{ \mathsf{ σ}}}_1+{\rm{ \mathsf{ σ}}}_2+\varpi_0+\varpi_1). $

    $ Ξ1=A<0,Ξ2=B<0,Ξ3=B1<0,Ξ4=B2<0,Ξ5=B3<0,Ξ6=B4<0.
    $

    When $ \mathcal{R}_0 > 1 $ the real parts of eigenvalues are negative, hence the model (2.1) is asymptotically locally stable at $ D_1 $ [38].

    Theorem 9. If $ \mathcal{R}_0 $ is greater than 1, then EE point $ D_1 $ is globally asymptotically stable and is not stable if less than 1.

    Proof. In order to show the asymptotic global stability of the considered model (2.1) at EE point $ D_1 $, we utilize the Castillo-Chavez technique [39,40]. Now let us take the sub-system of (2.1),

    $ dS(t)dt=ϕη1ISη2ϕASη3qHSη4CSϖ0S,dE(t)dt=η1IS+η2ϕAS+η3qHS+η4CS(ξ+ϖ0)E,dI(t)dt=ξρE(σ1+σ2)I(ϖ0+ϖ1)I.
    $
    (4.6)

    Consider $ \mathcal{P} $ and $ \mathcal{P}^{\mid2\mid} $ be the linearized matrix and second-additive of the model which contains the first three equations of system (2.1), which becomes

    $ P=(δ110δ13δ21δ22δ2300δ33),P2=((δ11+δ22)δ23δ13δ32(δ11+δ33)δ12δ31δ21(δ22+δ33)).
    $
    (4.7)

    Let $ \mathbb{Q}(\chi) = { \mathbb{Q}}(\mathrm{S}(t), \mathrm{E}(t), \mathrm{I}(t)) = diag\left\{\frac{\mathrm{S}}{\mathrm{E}}, \frac{\mathrm{S}}{\mathrm{E}}, \frac{\mathrm{S}}{\mathrm{E}}\right\}, $ then $ { \mathbb{Q}}^{-1}(\chi) = diag\left\{\frac{\mathrm{E}}{\mathrm{S}}, \frac{\mathrm{E}}{\mathrm{S}}, \frac{\mathrm{E}}{\mathrm{S}}\right\}, $ the derivative of $ { \mathbb{Q}}_f(\chi) $ w.r.t time, implies that

    $ Qf(χ)=diag{˙SE˙ESE2,˙SE˙ESE2,˙SES˙EE2}.
    $
    (4.8)

    Now $ { \mathbb{Q}}_f{ \mathbb{Q}}^{-1} = diag\{K_{1}, K_{1}, K_{1}\} $ and $ \mathbb{Q}\mathcal{P}^{\mid2\mid}_2 \mathbb{Q}^{-1} = \mathcal{P}^{\mid2\mid}_2 $, where $ K_{1} = \dot{\mathrm{S}}{\mathrm{S}}-\frac{\dot{\mathrm{E}}}{\mathrm{E}} $ $ {\bf A} = \mathbb{Q}_f \mathbb{Q}^{-1}+ \mathbb{Q}\mathcal{P}^{\mid2\mid}_2 \mathbb{Q}^{-1} $, and

    $ \begin{array}{l}  \;\; \;\;  \;\; \;\;\;\;\;\;\;\;\;\;{\bf A} = \left(\begin{array}{cc} {\bf A}_{11} & {\bf A}_{12}\\ {\bf A}_{21} & {\bf A}_{22} \end{array}
    \right), \\ {\bf A}_{11} = \frac{\dot{\mathrm{S}}}{\mathrm{S}}-\frac{\dot{\mathrm{E}}}{\mathrm{E}}-\eta_1\mathrm{I}-\eta_2{\rm{ \mathsf{ ϕ}}}\mathit{A}-\eta_3q\mathrm{H}-(\nu+\varpi_0), \\ {\bf A}_{12} = \left[η1Sη2S
    \right], \; \mathit{A}_{21} = \left[ ξρ0
    \right], \\ \;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\; {\bf A}_{22} = \left[ u110u21u22
    \right]. \\ \;\;\;\;\;\;\;\; {u}_{11} = \frac{\dot{\mathrm{S}}}{\mathrm{S}}-\frac{\dot{\mathrm{E}}}{\mathrm{E}}-\eta_1\mathrm{I}-\eta_2{\rm{ \mathsf{ ϕ}}}\mathit{A}-\eta_3 q\mathrm{H}-\varpi_0 , \\ \;\;\;\;\;\;\;\;{u}_{21} = \eta_1 \mathrm{I}-\eta_2{\rm{ \mathsf{ ϕ}}}\mathit{A}-\eta_3 q \mathrm{H}-\eta_4\mathrm{C}, \\ \;\;\;\;\;\;\;\;{u}_{22} = \frac{\dot{\mathrm{S}}}{\mathrm{S}}-\frac{\dot{\mathrm{E}}}{\mathrm{E}}-\xi-2\varpi_0. \end{array} $
    (4.9)

    Let $ ({n}_1, {n}_2, {n}_3) $ be vector $ in $ $ R^{3} $ and $ \|.\| $ of $ ({n}_1, {n}_2, {n}_3) $ presented by,

    $ n1,n2,n3=max{n1,n2+n3}.
    $
    (4.10)

    Here we consider the Lozinski-measure introduced in [41], $ \delta({\bf A})\leq sup\{{\varrho}_1, {\varrho}_2\} = sup\{\delta({\bf A}_{11})+\|{\bf A}_{12}\|, \delta({\bf A}_{22})+\|{\bf A}_{21}\|\}, $ where $ h_i = \delta({\bf A}_{ii})+\|{\bf A}_{ij}\| $ for $ i = 1, 2 $ and $ i\neq j, $ $ \Rightarrow $

    $ ϱ1=δ(A11)+A12,ϱ2=δ(A22)+A21,
    $
    (4.11)

    where $ \delta({\bf A}_{11}) = \frac{\dot{\mathrm{S}}}{\mathrm{S}}-\frac{\dot{\mathrm{E}}}{\mathrm{E}}-\eta_1\mathrm{I}-\eta_2{\rm{ \mathsf{ ϕ}}} \mathit{A}-\eta_3q\mathrm{H}-(\xi+\varpi_0) $, $ \delta({\bf A}_{22}) = max \left\{\frac{\dot{\mathrm{S}}}{\mathrm{S}}-\frac{\dot{\mathrm{E}}}{\mathrm{E}}-\eta_1\mathrm{I}-\eta_2{\rm{ \mathsf{ ϕ}}} \mathit{A}-\eta_3 q\mathrm{H}-\varpi_0, \eta_1 \mathrm{I}-\eta_2{\rm{ \mathsf{ ϕ}}} \mathit{A}-\eta_3 q \mathrm{H}-\eta_4 \mathrm{C} \right\}\\ = \frac{\dot{\mathrm{S}}}{\mathrm{S}}-\frac{\dot{\mathrm{E}}}{\mathrm{E}}-\eta_1\mathrm{I}-\eta_2{\rm{ \mathsf{ ϕ}}} \mathit{A}-\eta_3 q\mathrm{H}-\eta_4 \mathrm{C}\} $, $ \|{A} _{12}\| = \eta_1\mathrm{S} $ and $ \|{\bf A}_{21}\| = max\{\xi{\rm{ \mathsf{ ρ}}}, 0\} = \xi{\rm{ \mathsf{ ρ}}}. $ Therefore $ {\varrho}_1 $ and $ {\varrho}_2 $ become, i.e, $ {\varrho}_1\leq\frac{\dot{\mathrm{S}}}{\mathrm{S}}-2\varpi_0-\xi{\rm{ \mathsf{ ρ}}} $ and $ {\varrho}_2\leq\frac{\dot{\mathrm{S}}}{\mathrm{S}}-2\varpi_0-\xi-min\{{\rm{ \mathsf{ σ}}}_1, \nu{\rm{ \mathsf{ ρ}}}\} $, which presents $ \delta({\bf A})\leq\left\{\frac{\dot{\mathrm{S}}}{\mathrm{S}}+{\rm{ \mathsf{ σ}}}_1-min\{\xi, {\rm{ \mathsf{ σ}}}_1\}-2\varpi_0\right\}. $ Hence $ \delta({B})\leq\frac{\dot{\mathrm{S}}}{\mathrm{S}}-2\varpi_0 $. Integrating $ \delta({\bf A}) $ in $ [0, t] $ and also considering $ \lim_{t\rightarrow \infty}, $ we have

    $ limtsupsup1tt0δ(A)dt<2ϖ0,ˉk=limtsupsup1tt0δ(A)dt<0.
    $
    (4.12)

    So that the system of the first three compartments of model (2.1) is globally asymptotically stable.

    To find the relation of parameters to $ {\mathcal{R}_0} $ in the disease transmission we use the formula $ \Delta^{\mathcal{R}_0}_h = \frac{\partial \mathcal{R}_0}{\partial k}\frac{h}{\mathcal{R}_0} $ where $ h $ is the parameter, introduced by [34,35]. This makes it easy to identify the variables that have a substantial impact on reproduction number, using the above formula we have

    $ ΔR0η1=R0η1η1R0=0.60143>0,ΔR0η2=R0η2η2R0=0.0020302>0,ΔR0η3=R0η3η3R0=0.083624>0,ΔR0η4=R0η4η4R0=0.90820>0,ΔR0ξ=R0ξξR0=0.130434>0,ΔR0ϖ2=R0ϖ2ϖ2R0=1.002654<0,ΔR0ϖ0=R0ϖ0ϖ0R0=1.33673<0,ΔR0ϖ1=R0tϖ1ϖ1R0=0.0043>0,ΔR0ψ1=R0ψ1ψ1R0=0.006549>0,ΔR0ϕ=R0ϕϕR0=.9999999997>0,ΔR0ψ2=R0ψ2ψ2R0=0.996194>0,ΔR0ν=R0ννR0=0.843190<0,ΔR0σ1=R0σ1σ1R0=0.012374<0,ΔR0σ2=R0σ2σ2R0=0.00773<0.
    $
    Figure 1.  The graphs show the affect of various parameters on $ {\mathcal{R}_0} $ and the variations in them.

    These demonstrate the relevance of many factors in disease transmission. It also measures the change in $ {\mathcal{R}_0} $ as a function of a parameter modification. The sensitivity indices show that there is indeed a direct relationship between $ {\mathcal{R}_0} $ and a set of variables $ S_1 = [{\eta_1, \eta_2, \eta_3, \eta_4, \phi, \psi_1, \psi_2}] $, while has an inverse relation with $ \mathrm{S}_2 = [{\varpi_0, \varpi_2, {\rm{ \mathsf{ σ}}}_1, {\rm{ \mathsf{ σ}}}_2, \nu}] $. This demonstrates that higher the value of parameters $ \mathrm{S}_1 $ increases the value of threshold quantity greatly, but increasing the value for parameters $ \mathrm{S}_ 2 $ decreases the value of threshold value.

    Figure 2.  The graphs show the affect of various parameters on $ {\mathcal{R}_0} $ and the variations in them.

    In this part, we validate our analytical conclusion. We employ the Runge-Kutta technique of fourth order [42]. Some factors are chosen for demonstration purposes, while others are derived from publicly available data. The parameters are chosen in a way that is more biologically realistic. For the simulation, we use the following parameters. $ {\rm{ \mathsf{ ϕ}}} = 0.00004; \eta_1 = 0.007; \varpi_0 = 0.0003; \eta_2 = 0.003;$ $ \psi_2 = 0.00008; \varpi_1 = 0.0001; \eta_3 = 0.005; \xi = 0.002; $ $\eta_4 = 0.0001; {\rm{ \mathsf{ σ}}}_2 = 0.000001; \phi = 0.016; q = 0.00007; \varpi_2 = 0.00003; {\rm{ \mathsf{ σ}}}_1 = 0.001; {\rm{ \mathsf{ σ}}}_3 = 0.0007; $ $ \psi_1 = 0.0006; \nu = 0.000002. $ Figures 3 and 4 depict the performance of the proposed model based on the aforementioned parameters, which validate the theorem's analytical discovery (4.2). According to the theoretical understanding of these findings, whenever $ \mathrm{R}_0 < 1, $ each curve of solution of the sensitive population takes 150–300 days to achieve equilibrium. Likewise, the exposed community takes 250 to 150 days, the infected populace takes 200 to 100 days, and the asymptomatic populace, hospitalized, and recovered requires 100 to 50 days. Camel dynamics initially grow and then achieve an equilibrium state, as seen in illustration 0.

    Figure 3.  The demonstration of dynamics of $ \mathrm{S}, \mathrm{I}, \mathrm{E}, \mathrm{A} $ compartments population in case $ \mathcal{R}_0 < 1 $.
    Figure 4.  The demonstration of dynamics of various compartments populations (Hospitalized individuals, Recovered population, and Reservoir (MERS CoV), such that camel's in case $ \mathcal{R}_0 < 1 $).

    Next, we consider the parameters $ \eta_1 = 0.007; $ $ {\rm{ \mathsf{ σ}}}_1 = 0.001; $ $ \varpi_1 = 0.0001; $ $ \psi_1 = 0.0006; $ $ \eta_2 = 0.003; $ $ \varpi_2 = 0.00003; $ $ {\rm{ \mathsf{ ϕ}}} = 0.00004; $ $ {\rm{ \mathsf{ σ}}}_2 = 0.000001; $ $ \eta_3 = 0.005; $ $ \varpi_0 = 0.0003; $ $ \eta_4 = 0.0001; $ $ \xi = 0.002; $ $ \phi = 0.016; $ $ {\rm{ \mathsf{ σ}}}_3 = 0.0007; $ $ q = 0.00007; $ $ \nu = 0.000002. $ $ \psi_2 = 0.00008; $ and find $ \mathcal{R}_0 = 9.89887 $ which is greater than $ 1 $. We investigate the dynamics of the given model in the vicinity of the EE point. The numerical simulations based on the aforementioned settings are displayed in Figures (5) and (6), which validate the finding presented in Theorem (8).

    Figure 5.  The demonstration of dynamics of $ \mathrm{S}, \mathrm{I}, \mathrm{E}, \mathrm{A} $ compartments populations in case $ \mathcal{R}_0 > 1 $.
    Figure 6.  The demonstration of dynamics of various compartments population (Hospitalized individuals, Recovered populace, and (MERS CoV) reservoir, such that camel's in case $ \mathcal{R}_0 > 1 $).

    We develop control techniques based on sensitivity as well as model dynamics (2.1). The maximal sensitivity indices parameter is ($ \eta_1, \eta_2, \eta_3, \eta_4 $), and increasing this value by 10 percent, raises the threshold value. To limit the progress of the illness, we must minimize these parameters by using the control variables $ \mathbb{E}_1(\mathrm{t}), \mathbb{E}_2(\mathrm{t}), \mathbb{E}_3(\mathrm{t}), \mathbb{E}_4(\mathrm{t}) $ to represent (awareness about the mask, isolation people (infected), oxygen therapies, ventilation and self-care from the camels.)

    Our main goals are the reduction of MERS-CoV in the populace with increasing $ \mathrm{R}(\mathrm{t}) $ and decreasing $ \mathrm{I}(\mathrm{t}) $, $ \mathit{A}(\mathrm{t}) $ and $ \mathrm{H}(\mathrm{t}) $, reservoir $ \mathrm{C}(\mathrm{t}) $ with applying control parameters (time-dependent) $ \mathbb{E}_1(\mathrm{t}), \mathbb{E}_2(\mathrm{t}), \mathbb{E}_3(\mathrm{t}), \mathbb{E}_4(\mathrm{t}) $.

    $ i. $ $ \mathbb{E}_1(\mathrm{t}) $ represents the control parameter (time-dependent) represents the awareness concerning surgical masks and hand washing.

    $ ii. $ $ \mathbb{E}_2(\mathrm{t}) $ represents the control parameter (time-dependent) represents quarantining of infected persons.

    $ iii. $ $ \mathbb{E}_3(\mathrm{t}) $ represents the control parameter (time-dependent) represents mechanical ventilation (oxygen therapy).

    $ iv. $ $ \mathbb{E}_4(\mathrm{t}) $ represents the control parameter (time-dependent) self-care that is keeping distance from camels, avoiding raw milk, or eating improperly cooked meat.

    By the use of these control parameters in our suggested optimal control problem which we obtain by modifying model (2.1):

    $ dS(t)dt=ϕη1IS(1E1(t))η2ϕAS(1E1(t))η3qHS(1E1(t))η4CS(1E1(t))ϖ0S,dE(t)dt=η1IS(1E1(t))+η2ϕAS(1E1(t))+η3qHS(1E1(t))+η4CS(1E1(t))(ξ+ϖ0+E1(t))E,dI(t)dt=ξρE(σ1+σ2)I(ϖ0+ϖ1)IE2(t)I,dA(t)dt=ξE(1ρ)(ν+ϖ0)AE2(t)A,dH(t)dt=σ1I+νA(σ3+ϖ0)HE3(t)H,dR(t)dt=σ1IE2(t)+σ3HE3(t)ϖ0R,dC(t)dt=ψ1I+ψ2Aϖ2C(t)E4(t)C(t),
    $
    (6.1)

    with the initial conditions

    $ Ics={S(0),I(0),E(0),H(0),A(0),C(0),R(0)}0
    $

    The purpose here is to demonstrate that it is feasible to apply time-dependent control mechanisms while reducing the expense of doing so. We assume that the expenses of control schemes are nonlinear and take a quadratic shape, [43], which are cost variables that balance the size and importance of the sections of the optimization problem. As a result, we select the observable (cost) function as,

    $ J(E1,E2,E3,E4)=T0[ζ1I+ζ2A+ζ3H+ζ4C+12(ζ5E21(t)+ζ6E22(t)+ζ7E23(t)+ζ8E24(t)]dt.
    $
    (6.2)

    In Eq (6.2) $ \zeta_1 $, $ \zeta_2 $, $ \zeta_3 $, $ \zeta_4 $, $ \zeta_5 $, $ \zeta_6 $, $ \zeta_7 $, $ \zeta_8 $, stand for weight constants. $ \zeta_1 $, $ \zeta_2 $, $ \zeta_3 $, $ \zeta_4 $ express relative costs of infected ($ \mathrm{I} $), asymptomatic ($ \mathrm{A} $), hospitalized ($ \mathrm{H} $) and reservoir ($ \mathrm{C} $), while $ \zeta_5 $, $ \zeta_6 $, $ \zeta_7 $, $ \zeta_8 $ show associated-cost of control parameters. $ \frac{1}{2}\zeta_5 \mathbb{E}_1^2 $, $ \frac{1}{2}\zeta_8 \mathbb{E}_4^2 $, $ \frac{1}{2}\zeta_6 \mathbb{E}_2^2 $, $ \frac{1}{2}\zeta_7 \mathbb{E}_3^2 $, describe self care, treatment and isolation.

    Our objective is to obtain OC pair $ \mathbb{E}_1^{*} $, $ \mathbb{E}_2^{*} $, $ \mathbb{E}_3^{*} $, $ \mathbb{E}_4^{*} $, i.e.,

    $ J(E1,E2,E3,E4)=min{J(E1,E2,E3,E4),E1,E2,E3,E4U},
    $
    (6.3)

    dependent on model (6.1), we consider, the control-set of parameters as:

    $ U={(E1,E2,E3,E4)/uI(t)is Lebesgue-measurable on the[0,1],0uI(t)1,i=1,2,3,4}.
    $
    (6.4)

    We obey the result [44], stating that the solution of the system exists in the case when control parameters are bounded as well as Lebesgue measurable. So, we consider that the suggested control system can be presented as:

    $ \frac{d\Omega}{dt} = \mathrm{A}\Omega+\mathscr{B}\Omega. $

    In above system $ \Omega = (\mathrm{S}, \mathrm{I}, \mathrm{E}, \mathrm{H}, \mathrm{A}, \mathrm{C}) $, $ \mathrm{A}(\Omega) $ and $ \mathscr{B}(\Omega) $ represent linear and nonlinear bounded coefficient, respectively, so that

    $ A=[ϖ0000000y100000νρy20000ν(ρ+1)0y30000σ1ϵ(σ2+ϖ0+E3)000ψ1ψ20(θ+E4)],
    $
    (6.5)

    where $ y_1 = (\nu+\varpi_0+ \mathbb{E}_1) $, $ y_2 = ({\rm{ \mathsf{ σ}}}_1+{\rm{ \mathsf{ σ}}}_2+\varpi_0+\varpi_1+ \mathbb{E}_2) $, $ y_3 = (\epsilon+\varpi_0+\varpi_2+ \mathbb{E}_2). $

    $ B(Ω)=(ϕη1IS(1E1(t))ηθAϕS(1E1(t))η3qHS(1E1(t))η4CS(1E1(t))η1IS(1E1(t))+η2ϕAS(1E1(t))+η3qHS(1E1(t))+η4CS(1E1(t))0000).
    $

    Considering $ L(\Omega) = F\Omega + A\Omega, $

    $ |F(Ω1)F(Ω2|p1|S1S2|+p2|E1E2|+p3|I1I2|+p4|A1A2|+p5|H1H2|+p6|C1C2|P|S1S2|+|E1E2|+|C1C2|+|I1I2|+|H1H2|+|A1A2|.
    $

    Here $ P = max(p_1, p_2, p_3, p_4, p_5, p_6, p_7, p_8) $ does not depend on the suggested model state-classes. We can also express

    $ |L(\Omega_1)-L(\Omega_2)|\leq|W(\Omega_1)-W(\Omega_2)|, $

    where $ W = (P, \|A\|) $ is less than $ \infty, $ $ L $ is continuous in the Lipschitz sense, and from the description the system classes are non-negative, it obviously shows that the solution of model (6.1) exists. For the existence of the solution let us consider, and prove the following theorem:

    Theorem 10. There exist an OC $ \mathbb{E}^{*} = (\mathbb{E}_1^{*}, \mathbb{E}_2^{*}, \mathbb{E}_3^{*}, \mathbb{E}_4^{*})\in \mathbb{E} $, to control-system presented in Eqs (6.1) and (6.2).

    Proof. As it is obvious that the control and system variables are not negative. It is also worth noting that U (set of variables) is closed and convex by expression. Furthermore, the control problem is bounded, indicating the problem's compactness. The expression $ \zeta_1\mathrm{I}+\zeta_2\mathrm{A}+\zeta_3\mathrm{H}+\zeta_4\mathrm{C}+\frac{1}{2}(\zeta_5 \mathbb{E}_1^2(\mathrm{t})+\zeta_6 \mathbb{E}_2^2(\mathrm{t})+\zeta_7 \mathbb{E}_3^2(\mathrm{t})+\zeta_8 \mathbb{E}_4^2(\mathrm{t}) $ is convex as well, w.r.t the set $ U $. It guarantees the existence of OC for OC variables $ (\mathbb{E}^{*}_1, \mathbb{E}^{*}_2, \mathbb{E}^{*}_3, \mathbb{E}^{*}_4) $.

    Here, we determine the best solution to control problems (6.1) and (6.2). For this, we employ the Lagrangian, and Hamiltonian equations, as shown below:

    $ L(I,C,A,H,E1,E2,E3,E4)=ζ1I+ζ2A+ζ3H+ζ4C+12(ζ5E21(t)+ζ6E22(t)+ζ7E23(t)+ζ8E24(t).
    $

    To define the Hamiltonian (H) associated with the model, we use the notion $ \Theta $ = $ (\Theta_1, \Theta_2, \Theta_3, \Theta_4, \Theta_5, \Theta_6, \Theta_7) $ and $ \Upsilon = (\Upsilon_1, \Upsilon_2, \Upsilon_3, \Upsilon_4, \Upsilon_5, \Upsilon_6, \Upsilon_7) $ then,

    $ H(x,u,Θ)=L(x,u)+ΘΥ(x,u),
    $

    where

    $ Υ1(x,u)=ϕη1IS(1E1(t))η2ϕAS(1E1(t))η3qHS(1E1(t))η4CS(1E2(t))ϖ0S,Υ2(x,u)=η1IS(1E1(t))+η2ϕAS(1E1(t))+η3qHS(1E1(t))+η4CS(1E2(t))(ξ+ϖ0+E1)E,Υ3(x,u)=ξρE(σ1+σ2)I(ϖ0+ϖ1)IE2(t)I(t),Υ4(x,u)=ξ(1ρ)E(ν+ϖ0)AE2(t)A,Υ5(x,u)=σ1I+νA(σ3+ϖ0)HE3(t)H,Υ6(x,u)=σ1IE2(t)+σ3HE3(t)ϖ0R,Υ7(x,u)=ψ1I+ψ2Aϖ2CE4(t)C(t),
    $
    (6.6)

    and $ \mathfrak{Z}(x, u) = \Upsilon_1(x, u), \Upsilon_2(x, u), \Upsilon_3(x, u), \Upsilon_4(x, u), \Upsilon_5(x, u), \Upsilon_6(x, u), \Upsilon_7(x, u) $.

    Here we utilize, the principle [45,46] to Hamiltonian, in order to obtain an optimality solution, which is stated that if the solution expressed with $ (x^*, u^*) $ is optimal, then $ \exists $ a function $ \Theta $, such that

    $ ˙x=HΘ,0=Hu,ΘA(t)=Hx.H(t,x,u,Θ)x=maxE1,E2,E3,E4[0,1]H(x(t),E1,E2,E3,E4,ΘA(t));
    $
    (6.7)

    and the condition of transversality

    $ Θ(tf)=0.
    $
    (6.8)

    Thus to obtain the adjoint variables and OC variables, we use the principles Eq (6.7). So we get

    Theorem 11. Suppose that optimal and control-parameters are expressed by $ \mathrm{S}^{*} $, $ \mathrm{E}^{*} $, $ \mathrm{A}^{*} $, $ \mathrm{I}^{*} $, $ \mathrm{H}^{*} $, $ \mathrm{C}^{*} $, $ \mathrm{R}^{*} $ be the optimal-state $ (\mathbb{E}_1^{*}, \mathbb{E}_2^{*}, \mathbb{E}_3^{*}, \mathbb{E}_4^{*}) $ for system (6.1)-(6.2). Then $ \Theta\mathrm{A}(\mathrm{t}) $ (adjoint variables set) satisfies:

    $ Θ1(t)=(Θ1Θ2)(η1I+η2ϕA+η3qH+η4C)(1E1)(t)+Θ1ϖ0,Θ2(t)=(Θ2Θ4)ξ+(Θ4Θ3)ξρ+Θ2ϖ0+Θ2E1(t),Θ3(t)=ζ1+(Θ1Θ2)η1S(1E1(t))+(Θ3Θ5)σ1Θ6ξ1E2(t)Θ7Θ4(t)=ζ2+(Θ1Θ2)η2ϕS(1E1(t))+(Θ4Θ5)ν+Θ4(ϖ0+E2(t))Θ7ψ2,Θ5(t)=ζ3(Θ1Θ2)η3qS(1E1(t))+(σ3+u0+E3(t))Θ5Θ6σ3E3(t),Θ6(t)=ϖ0Θ6,Θ7(t)=ζ4+(Θ1Θ2)η4S(1E1(t))+Θ7(ϖ2+E4(t)),
    $
    (6.9)

    having terminal condition

    $ ΘA(t)=0.
    $
    (6.10)

    The OC variables $ \mathbb{E}_1^{*}(\mathrm{t}) $, $ \mathbb{E}_2^{*}(\mathrm{t}) $, $ \mathbb{E}_3^{*}(\mathrm{t}) $, $ \mathbb{E}_4^{*}(\mathrm{t}) $ are

    $ E1(t)=max[min[(Θ2Θ1)η1IS+η2ϕA+η3qH+η4CS+Θ2Eζ5,1],0],E2(t)=max[min[(Θ3I+Θ6σ1R+Θ4A+Θ5H)ζ6,1],0],E3(t)=max[min[(Θ5HΘ6σR)ζ7,1],0],E4(t)=max[min[(Θ7C)ζ8,1],0].
    $
    (6.11)

    Proof: The adjoint-model (6.9) is obtained by applying the principle (6.7) and the transversality conditions from the outcomes of $ \Theta\mathrm{A}(\mathrm{t}) = 0 $. For optimal functions set $ \mathbb{E}_1^*, \mathbb{E}_2^*, \mathbb{E}_3^* $ and $ \mathbb{E}_4^*, $ we utilized $ \frac{\partial \mathrm{H}}{\partial u} $. In the next part, we evaluate the optimality problem numerically. Since it will be easier for such readers to understand as compared to analytical data. The optimization problem system is defined by its control-system (6.1), adjoint-system (6.9), boundary conditions, and OC functions.

    Using the RK technique of order four, we calculate the optimal control model (6.1) to observe the influence of masks, treatment, isolations, and self-care from camels. We employ the forward RK technique to get the solution of system (2.1) with starting conditions in the time interval [0, 50]. To obtain a solution to the adjoint-system (6.9), we apply the backward RK technique in the same domain with the assistance of the transversality constraint. For simulation purposes, we consider the parameters as: $ \nu = 0.0071; $ $ \varpi_1 = 0.014567125; $ $ \eta_1 = 0.00041; $ $ \eta_3 = 0.0000123; $ $ \eta_4 = 0.0000123; $ $ \theta = 0.98; $ $ {\rm{ \mathsf{ σ}}}_1 = 0.0000404720925; $ $ {\rm{ \mathsf{ σ}}}_3 = 0.00135; $ $ q = 0.017816; $ $ \psi_1 = 0.05; $ $ \varpi_0 = 0.00997; $ $ \eta_2 = 0.0000123; $ $ \phi = 0.003907997; $ $ {\rm{ \mathsf{ σ}}}_2 = 0.000431; $ $ {\rm{ \mathsf{ ρ}}} = 0.00007; $ $ \varpi_2 = 0.014567125 $ $ \psi_2 = 0.06; $. These parameters are considered in such a manner that more feasible biologically. Weight constants, here are taken as $ \zeta_1 = 0.6610000; $ $ \zeta_2 = 0.54450; $ $ \zeta_3 = 0.0090030; $ $ \zeta_4 = 0.44440; $ $ \zeta_6 = 0.3550; $ $ \zeta_7 = 0.67676; $ $ \zeta_8 = 0.999. $ So we get the upcoming behaviours shown in Figures 7a, 7b, 7c, 7d, 8a, 8b, 8c.

    Figure 7.  The graphs depict the dynamic of the classes with control and without controls.
    Figure 8.  The graphs depict the dynamic of the classes with control and without controls.

    These figures reflect the dynamics of susceptibles, exposed, infected people, asymptomatic persons, hospitalized, recovered, and MERS reservoirs, i.e., camels with and also without control. Our major goal in using the OC tool is to reduce the number of persons who are infected while increasing the number of those who are not infected, as demonstrated by numerical findings.

    In this study, we developed a mathematical model to analyze the transmission of MERS-CoV between people and its reservoir (camels), with the goal of assessing the transmission risk of MERS-CoV. We calculated the model's fundamental reproductive number, $ \mathcal{R}_0 $, and employed stability theory to examine the local and global behavior of the model and determine the conditions that lead to stability. We also evaluated the sensitivity of $ \mathrm{R}_0 $ to understand the impact of each epidemiological parameter on disease transmission. To minimize the number of infected individuals and intervention costs, we incorporated optimal control into the model, which included time-dependent control variables such as supportive care, surgical masks, treatment, and public awareness campaigns about the use of masks. Furthermore, our biological interpretation of the results indicates that if the basic reproduction number is less than one, the susceptible population decreases for up to 60 days, and then becomes stable, indicating that the population will remain stable. Our numerical simulations validated the effectiveness of our control strategies in reducing the number of infected individuals, asymptomatic cases, hospitalizations, and MERS-CoV reservoir, while increasing the susceptible and recovered populations. These simulations support our analytical work.

    This study is supported via funding from Prince Sattam bin Abdulaziz University project number PSAU/2023/R/1444.

    [1] Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79: 368-376. doi: 10.1136/jnnp.2007.131045
    [2] de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535. doi: 10.1016/S1474-4422(06)70471-9
    [3] Davie CA (2008) A review of Parkinson's disease. Br Med Bull 86: 109-127. doi: 10.1093/bmb/ldn013
    [4] Aarsland D, Beyer MK, Kurz MW (2008) Dementia in Parkinson's disease. Curr Opin Neurol 21: 676-682. doi: 10.1097/WCO.0b013e3283168df0
    [5] Adler CH, Dugger BN, Hinni ML, et al. (2014) Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 82: 858-864. doi: 10.1212/WNL.0000000000000204
    [6] Aerts MB, Esselink RA, Abdo WF, et al. (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33: 430 e431-433.
    [7] Mollenhauer B, Cullen V, Kahn I, et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325. doi: 10.1016/j.expneurol.2008.06.004
    [8] van Dijk KD, Bidinosti M, Weiss A, et al. (2014) Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 21: 388-394.
    [9] Gerlach M, Maetzler W, Broich K, et al. (2012) Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 119: 39-52. doi: 10.1007/s00702-011-0682-x
    [10] Gao L, Chen H, Li X, et al. (2015) The diagnostic value of minor salivary gland biopsy in clinically diagnosed patients with Parkinson's disease: comparison with DAT PET scans. Neurol Sci.
    [11] Folgoas E, Lebouvier T, Leclair-Visonneau L, et al. (2013) Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology. Neurosci Lett 551: 62-64. doi: 10.1016/j.neulet.2013.07.016
    [12] Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26: 201-204.
    [13] Sherer Y, Gorstein A, Fritzler MJ, et al. (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34: 501-537. doi: 10.1016/j.semarthrit.2004.07.002
    [14] Diamond B, Huerta PT, Mina-Osorio P, et al. (2009) Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 9: 449-456. doi: 10.1038/nri2529
    [15] Tan HT, Low J, Lim SG, et al. (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276: 6880-6904. doi: 10.1111/j.1742-4658.2009.07396.x
    [16] Levin EC, Acharya NK, Han M, et al. (2010) Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 1345: 221-232. doi: 10.1016/j.brainres.2010.05.038
    [17] Nagele EP, Han M, Acharya NK, et al. (2013) Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 8: e60726. doi: 10.1371/journal.pone.0060726
    [18] Lacroix-Desmazes S, Mouthon L, Kaveri SV, et al. (1999) Stability of natural self-reactive antibody repertoires during aging. J Clin Immunol 19: 26-34. doi: 10.1023/A:1020510401233
    [19] Mirilas P, Fesel C, Guilbert B, et al. (1999) Natural antibodies in childhood: development, individual stability, and injury effect indicate a contribution to immune memory. J Clin Immunol 19: 109-115. doi: 10.1023/A:1020554500266
    [20] Avrameas S (1991) Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 12: 154-159.
    [21] Avrameas S, Ternynck T, Tsonis IA, et al. (2007) Naturally occurring B-cell autoreactivity: a critical overview. J Autoimmun 29: 213-218. doi: 10.1016/j.jaut.2007.07.010
    [22] Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 ( Pt 5): 2283-2301.
    [23] Postuma RB, Gagnon JF, Montplaisir J (2010) Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 81: 1008-1013. doi: 10.1136/jnnp.2009.174748
    [24] Nagele E, Han M, Demarshall C, et al. (2011) Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 6: e23112. doi: 10.1371/journal.pone.0023112
    [25] Han M, Nagele E, DeMarshall C, et al. (2012) Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One 7: e32383. doi: 10.1371/journal.pone.0032383
    [26] DeMarshall CA, Han M, Nagele EP, et al. (2015) Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. Immunol Lett 168: 80-88. doi: 10.1016/j.imlet.2015.09.010
    [27] Rice JS, Kowal C, Volpe BT, et al. (2005) Molecular mimicry: anti-DNA antibodies bind microbial and nonnucleic acid self-antigens. Curr Top Microbiol Immunol 296: 137-151.
    [28] Nagele RG, Clifford PM, Siu G, et al. (2011) Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta(1-42) deposition. J Alzheimers Dis 25: 605-622.
    [29] Nath A, Hall E, Tuzova M, et al. (2003) Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 3: 29-39. doi: 10.1385/NMM:3:1:29
    [30] Maftei M, Thurm F, Schnack C, et al. (2013) Increased levels of antigen-bound beta-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. PLoS One 8: e68996. doi: 10.1371/journal.pone.0068996
    [31] Maetzler W, Berg D, Synofzik M, et al. (2011) Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 26: 171-179.
    [32] Costa A, Bini P, Hamze-Sinno M, et al. (2011) Galanin and alpha-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease. J Neuroimmunol 240-241: 114-120. doi: 10.1016/j.jneuroim.2011.10.003
    [33] McIntyre JA, Ramsey CJ, Gitter BD, et al. (2015) Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. Autoimmunity 48: 344-351. doi: 10.3109/08916934.2015.1008464
    [34] Conradi S, Ronnevi LO (1993) Selective vulnerability of alpha motor neurons in ALS: relation to autoantibodies toward acetylcholinesterase (AChE) in ALS patients. Brain Res Bull 30: 369-371. doi: 10.1016/0361-9230(93)90267-F
    [35] Tzartos JS, Zisimopoulou P, Rentzos M, et al. (2014) LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol 1: 80-87. doi: 10.1002/acn3.26
    [36] Fialova L, Svarcova J, Bartos A, et al. (2010) Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur J Neurol 17: 562-566. doi: 10.1111/j.1468-1331.2009.02853.x
    [37] Lee DH, Heidecke H, Schroder A, et al. (2014) Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. Mol Neurodegener 9: 49. doi: 10.1186/1750-1326-9-49
    [38] Pollak TA, McCormack R, Peakman M, et al. (2014) Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med 44: 2475-2487. doi: 10.1017/S003329171300295X
    [39] Pearlman DM, Najjar S (2014) Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res 157: 249-258. doi: 10.1016/j.schres.2014.05.001
    [40] Levite M, Ganor Y (2008) Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis. Expert Rev Neurother 8: 1141-1160. doi: 10.1586/14737175.8.7.1141
    [41] Lee JY, Huerta PT, Zhang J, et al. (2009) Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med 15: 91-96. doi: 10.1038/nm.1892
    [42] Zimmerman AW, Connors SL, Matteson KJ, et al. (2007) Maternal antibrain antibodies in autism. Brain Behav Immun 21: 351-357. doi: 10.1016/j.bbi.2006.08.005
    [43] Braunschweig D, Ashwood P, Krakowiak P, et al. (2008) Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 29: 226-231.
    [44] Cabanlit M, Wills S, Goines P, et al. (2007) Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann N Y Acad Sci 1107: 92-103. doi: 10.1196/annals.1381.010
    [45] Singer HS, Morris CM, Williams PN, et al. (2006) Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 178: 149-155. doi: 10.1016/j.jneuroim.2006.05.025
    [46] Raad M, Nohra E, Chams N, et al. (2014) Autoantibodies in traumatic brain injury and central nervous system trauma. Neuroscience 281C: 16-23.
    [47] Kobeissy F, Moshourab RA (2015) Autoantibodies in CNS Trauma and Neuropsychiatric Disorders: A New Generation of Biomarkers. In: Kobeissy FHP, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL).
    [48] Zhang Y, Popovich P (2011) Roles of autoantibodies in central nervous system injury. Discov Med 11: 395-402.
    [49] Skoda D, Kranda K, Bojar M, et al. (2006) Antibody formation against beta-tubulin class III in response to brain trauma. Brain Res Bull 68: 213-216. doi: 10.1016/j.brainresbull.2005.05.032
    [50] Davies AL, Hayes KC, Dekaban GA (2007) Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil 88: 1384-1393. doi: 10.1016/j.apmr.2007.08.004
    [51] Spillantini MG, Schmidt ML, Lee VM, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840. doi: 10.1038/42166
    [52] Marui W, Iseki E, Kato M, et al. (2004) Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease. Acta Neuropathol 108: 121-128.
    [53] Ohrfelt A, Grognet P, Andreasen N, et al. (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450: 332-335. doi: 10.1016/j.neulet.2008.11.015
    [54] Hall S, Surova Y, Ohrfelt A, et al. (2015) CSF biomarkers and clinical progression of Parkinson disease. Neurology 84: 57-63. doi: 10.1212/WNL.0000000000001098
    [55] Mondello S, Constantinescu R, Zetterberg H, et al. (2014) CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 20: 382-387. doi: 10.1016/j.parkreldis.2014.01.011
    [56] Kruse N, Persson S, Alcolea D, et al. (2015) Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging 36: 2587-2596. doi: 10.1016/j.neurobiolaging.2015.05.003
    [57] Koehler NK, Stransky E, Meyer M, et al. (2015) Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One 10: e0123444. doi: 10.1371/journal.pone.0123444
    [58] Caranci G, Piscopo P, Rivabene R, et al. (2013) Gender differences in Parkinson's disease: focus on plasma alpha-synuclein. J Neural Transm 120: 1209-1215. doi: 10.1007/s00702-013-0972-6
    [59] Besong-Agbo D, Wolf E, Jessen F, et al. (2013) Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80: 169-175. doi: 10.1212/WNL.0b013e31827b90d1
    [60] Yanamandra K, Gruden MA, Casaite V, et al. (2011) alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 6: e18513. doi: 10.1371/journal.pone.0018513
    [61] Smith LM, Schiess MC, Coffey MP, et al. (2012) alpha-Synuclein and anti-alpha-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One 7: e52285. doi: 10.1371/journal.pone.0052285
    [62] Double KL, Rowe DB, Carew-Jones FM, et al. (2009) Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 217: 297-301. doi: 10.1016/j.expneurol.2009.03.002
    [63] Zappia M, Crescibene L, Bosco D, et al. (2002) Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand 106: 54-57.
    [64] Hatano T, Saiki S, Okuzumi A, et al. (2015) Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry.
    [65] Luan H, Liu LF, Meng N, et al. (2015) LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease. J Proteome Res 14: 467-478. doi: 10.1021/pr500807t
    [66] Trupp M, Jonsson P, Ohrfelt A, et al. (2014) Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. J Parkinsons Dis 4: 549-560.
  • This article has been cited by:

    1. Herbert F. Jelinek, Andrei V. Kelarev, A Survey of Data Mining Methods for Automated Diagnosis of Cardiac Autonomic Neuropathy Progression, 2016, 3, 2375-1576, 217, 10.3934/medsci.2016.2.217
    2. Sok Kean Khoo, Biofluid-based Biomarkers for Parkinsons Disease: A New Paradigm, 2015, 2, 2375-1576, 371, 10.3934/medsci.2015.4.371
    3. Jolene Su Yi Tan, Yin Xia Chao, Olaf Rötzschke, Eng-King Tan, New Insights into Immune-Mediated Mechanisms in Parkinson’s Disease, 2020, 21, 1422-0067, 9302, 10.3390/ijms21239302
    4. Majid Ghareghani, Amir Ghanbari, Shima Dokoohaki, Naser Farhadi, Seyed Mojtaba Hosseini, Reza Mohammadi, Heibatollah Sadeghi, Methylprednisolone improves lactate metabolism through reduction of elevated serum lactate in rat model of multiple sclerosis, 2016, 84, 07533322, 1504, 10.1016/j.biopha.2016.11.042
    5. Andrei V. Kelarev, Xun Yi, Hui Cui, Leanne Rylands, Herbert F. Jelinek, A survey of state-of-the-art methods for securing medical databases, 2018, 5, 2375-1576, 1, 10.3934/medsci.2018.1.1
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6349) PDF downloads(1233) Cited by(5)

Figures and Tables

Figures(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog